Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, uppe… Read more
Marksans Pharma Limited - Asset Resilience Ratio
Marksans Pharma Limited (MARKSANS) has an Asset Resilience Ratio of 24.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Marksans Pharma Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Marksans Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹6.67 Billion | 19.36% |
| Short-term Investments | ₹1.90 Billion | 5.51% |
| Total Liquid Assets | ₹8.56 Billion | 24.88% |
Asset Resilience Insights
- Good Liquidity Position: Marksans Pharma Limited maintains a healthy 24.88% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Marksans Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Marksans Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 14.06% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
Annual Asset Resilience Ratio for Marksans Pharma Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Marksans Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.15% | ₹4.26 Billion | ₹32.40 Billion | +2.07pp |
| 2024-03-31 | 11.08% | ₹2.97 Billion | ₹26.81 Billion | -17.57pp |
| 2023-03-31 | 28.65% | ₹6.28 Billion | ₹21.90 Billion | +17.07pp |
| 2022-03-31 | 11.59% | ₹1.90 Billion | ₹16.40 Billion | +11.44pp |
| 2021-03-31 | 0.14% | ₹17.23 Million | ₹12.28 Billion | -0.05pp |
| 2020-03-31 | 0.19% | ₹17.23 Million | ₹8.97 Billion | +0.19pp |
| 2018-03-31 | 0.01% | ₹500.00K | ₹7.29 Billion | -0.01pp |
| 2017-03-31 | 0.01% | ₹897.08K | ₹7.52 Billion | -- |